Trevena Says On Oct. 1 Got Notification That IND Application For TRV045 Will Be Placed On Hold To Address Certain Phase 1 Study Design Elements; Says FDA Will Issue A Letter Within Next 30 Days Documenting Items That Need To Be Addressed